Expanding the frontier: a clinical dialogue on the IL-23 pathway in psoriatic arthritis


The main goals of this live evening event are to give physicians sufficient supportive information so they can choose the optimal treatment for their patients; to highlight the recently published outcomes of IL-23 blockade in psoriatic arthritis; to discuss the benefits of treating to target, and early diagnosis and treatment. In addition to presentations and interactive discussions, case studies will be used to reach these goals. We invite rheumatologists from around the world to tune in for the presentations and to interact with the faculty during the discussions and Q&A session.

Learning objectives

After this event, participants should be able to:

  • Understand how to navigate the evolving treatment landscape and how to optimally manage psoriatic arthritis
  • Analyse the safety and efficacy data from randomized clinical trials and real-world evidence for psoriatic arthritis treatment
  • Describe the benefits of treating to target and the use of biologics as early treatment for patients with psoriatic arthritis

Scientific Committee

  • Ennio Lubrano (Italy)
  • Philip J. Mease (USA)(Scientific Committee)
  • Carlo Selmi (Italy)(Scientific Committee)

Programme (all times in CEST)

20:00–20:05 Introduction
Carlo Selmi
20:05–20:15 Case 1
Carlo Selmi
20:15–20:20 Early does it!
Ennio Lubrano
20:20–20:30 Turning data into information
Philip Mease
20:30–20:40 Case 2
Carlo Selmi
20:40–20:50 Keeping your eye on the target
Ennio Lubrano
20:50–20:55 Q&A
Moderated by Carlo Selmi
20:55–21:00 Conclusion and close
Philip Mease

More Info
63 Minutes
EM-60785 - Date of preparation: April 2021